Medically reviewed on Jan 18, 2019
(KROE moe lin)
- Cromoglycic Acid
- Cromolyn Sodium
- Disodium Cromoglycate
- Sodium Cromoglicate
- Sodium Cromoglycate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic, as sodium:
Generic: 4% (10 mL)
- Mast Cell Stabilizer
Mast cell stabilizer that inhibits the in vivo and in vivo release of histamine and slow-reacting substance of anaphylaxis (SRS-A) associated with antigen-mediated reactions.
Onset of Action
Response to treatment: May be seen within a few days; treatment for up to 6 weeks is often required
Use: Labeled Indications
Conjunctivitis/keratitis: Treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis
Hypersensitivity to cromolyn or any component of the formulation
Conjunctivitis and keratitis: Ophthalmic: Instill 1 to 2 drops in each eye 4 to 6 times daily. Symptomatic response is often evident within a few days; continue therapy as long as required.
Refer to adult dosing.
Conjunctivitis and keratitis: Children ≥4 years and Adolescents: Ophthalmic: Instill 1 to 2 drops in each eye 4 to 6 times daily at regular intervals
For ophthalmic use only. Wash hands prior to use. Instill drops inside the lower eyelid; avoid instilling directly on the cornea. To avoid contamination, do not touch dropper tip to eye, eyelid, fingers, or any other surface. Do not wear contact lenses during treatment.
Store at 15°C to 25°C (59°F to 77°F). Protect from light. Store in original carton.
There are no known significant interactions.
Frequency not defined.
Ocular: Conjunctival injection, dryness around the eye, edema, eye irritation, immediate hypersensitivity reactions, itchy eyes, puffy eyes, styes, rash, watery eyes
Concerns related to adverse effects:
• Irritation: May cause transient burning or stinging upon instillation.
• Contact lens wearers: Some products may contain benzalkonium chloride which may be absorbed by contact lenses; do not wear contact lenses during treatment.
• Appropriate use: For topical ophthalmic use only; not for injection. To avoid contamination, do not touch dropper tip to eye, eyelid, fingers, or any other surface when placing drops in eyes.
Pregnancy Risk Factor
Adverse events have not been observed in animal reproduction studies following SubQ administration. Systemic absorption following ophthalmic application is limited (~0.03%).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience stinging or burning. Have patient report immediately to prescriber shortness of breath, vision changes, eye pain, severe eye irritation, or eye discharge (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about cromolyn ophthalmic
- Cromolyn ophthalmic Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Pricing & Coupons
- En Español
- Drug class: ophthalmic antihistamines and decongestants
Other brands: Crolom